This is a repository copy of Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/141205/

Version: Published Version

Article:
Hackinger, S., Prins, B., Mamakou, V. et al. (12 more authors) (2018) Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia. Translational Psychiatry, 8. 252. ISSN 2158-3188

https://doi.org/10.1038/s41398-018-0304-6

Reuse
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia

Sophie Hackinger1, Bram Prins2, Vasiliki Mamakou3,4, Eleni Zengini4,5, Eirini Marouli6, Luka Brčić7, Ioannis Serafetinidis8, Klea Lamnissou9, Vassilis Kontaxakis10, George Dedoussis11, Fragiskos Gonidakis12, Anastasia Thanopoulou13, Nikolaos Tentolouris14, Aspasia Tsezou15 and Eleftheria Zeggini1,16

Abstract
The epidemiologic link between schizophrenia (SCZ) and type 2 diabetes (T2D) remains poorly understood. Here, we investigate the presence and extent of a shared genetic background between SCZ and T2D using genome-wide approaches. We performed a genome-wide association study (GWAS) and polygenic risk score analysis in a Greek sample collection (GOMAP) comprising three patient groups: SCZ only (n = 924), T2D only (n = 822), comorbid SCZ and T2D (n = 505); samples from two separate Greek cohorts were used as population-based controls (n = 1,125). We used genome-wide summary statistics from two large-scale GWAS of SCZ and T2D from the PGC and DIAGRAM consortia, respectively, to perform genetic overlap analyses, including a regional colocalisation test. We show for the first time that patients with comorbid SCZ and T2D have a higher genetic predisposition to both disorders compared to controls. We identify five genomic regions with evidence of colocalising SCZ and T2D signals, three of which contain known loci for both diseases. We also observe a significant excess of shared association signals between SCZ and T2D at nine out of ten investigated p value thresholds. Finally, we identify 29 genes associated with both T2D and SCZ, several of which have been implicated in biological processes relevant to these disorders. Together our results demonstrate that the observed comorbidity between SCZ and T2D is at least in part due to shared genetic mechanisms.

Introduction
Schizophrenia (SCZ) patients are 1.5–2 times more likely to develop type 2 diabetes (T2D) compared to the general population1. Several explanations for this epidemiologic link have been proposed, including environmental factors, the use of antipsychotic medication, and/or shared genetic aetiology1–4. For example, patients with severe mental illness often lead a more sedentary life and are more likely to smoke compared to the general population4—both risk factors for T2D. Antipsychotic drugs, particularly second generation antipsychotics, are known to cause metabolic side effects and often lead to significant weight gain5. Several studies have found an association between psychotropic medication and T2D risk6–8, but it is still unclear to what extent interactions between different medications, lifestyle and inter-patient variability affect this association4. It is conceivable that the metabolic effects of antipsychotics are partly mediated by genetic predisposition. So far, studies on the genetics of antipsychotic response have been small (n < 400) and unable to identify replicating associations9,10.
In addition, there is evidence that the increased prevalence of T2D in patients with SCZ is not purely medication induced: Proteomic studies have revealed perturbed expression of genes involved in glucose metabolism in brain tissue and elevated insulin levels in peripheral blood of first-episode SCZ patients compared to controls. More recently, a large study following over 2.5 million Danish individuals found that antipsychotic-naïve SCZ patients were three times more likely to develop T2D than the general population, with antipsychotic drug use further increasing that risk. This, along with findings from a systematic review and meta-analysis, suggests that impaired glucose homeostasis may already be present in drug-naïve SCZ patients.

It is also plausible that the observed overlap between SCZ and T2D is due to common susceptibility variants. Both diseases are highly polygenic, and genome-wide association studies (GWAS) to date have successfully identified a substantial number of risk loci for T2D and SCZ. Functional analyses showed that risk variants for SCZ are enriched for enhancers mapping to pancreatic beta cells, and that variants associated with BMI—a key risk factor for T2D—predominantly map to central nervous system pathways. Genetic research into the shared pathobiology of SCZ and T2D has been limited to date, and has mainly focused on patients with one of the two disorders. If SCZ without T2D comorbidity and SCZ with T2D are partly underpinned by different genetic aetiologies, such study designs will fail to identify risk factors predisposing to the latter.

Here, we investigate the presence of shared genetic risk factors for T2D and SCZ using genotypic data from a novel cohort comprising three patient groups (T2D only, SCZ only, and comorbid SCZ and T2D), as well as summary data from large-scale disease-specific GWAS. First, we conduct genome-wide comparisons between all three patient groups, as well as population controls; next, we assess the genetic overlap between the two disorders using polygenic risk scores; finally, we use summary statistics from published GWAS to search for genetic risk factors shared between SCZ and T2D.

### Methods

#### Data sets

The GOMAP (Genetic Overlap between Metabolic and Psychiatric disorders) study comprises a collection of 2,747 DNA samples from four different patient categories: T2D patients, SCZ patients, individuals with both SCZ and T2D (referred to from here on as SCZplusT2D), and individuals with a different psychiatric diagnosis (this last group is not used in further analyses reported here) (Table 1). SCZ patients with and without T2D were recruited at the Dromokaitio Psychiatric Hospital and Dafni Psychiatric Hospital in Athens. SCZ diagnosis was determined by structured clinical interview of the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV). T2D participants were recruited from diabetes outpatient clinics at Hippokrateio General Hospital and Laiko General Hospital. T2D status was assessed in all participants based on criteria outlined by the American Diabetes Association. All participants gave written informed consent.

#### Quality control

A total of 2,474 samples and 538,448 markers were successfully genotyped on the Illumina HumanCoreExome 12v1.0 BeadChip (Illumina, San Diego, CA, USA) at the Wellcome Trust Sanger Institute, Hinxton, UK. Quality control (QC) of genotype data was performed following a standard protocol using the PLINK software package. Individuals were removed if they had a call rate below 90%, discordant values for genotyped and reported sex or had heterozygosity rates deviating more than three standard deviations from the mean. For duplicates and related sample pairs (pi_hat > 0.2), we excluded one and retained the other.

In order to identify potential ethnic outliers, we performed multidimensional scaling (MDS) on a merged dataset comprising GOMAP and three other Greek sample collections: TEENAGE, a collection of adolescents from the general Greek population, HELIC-POMAK and HELIC-MANOLIS, two Greek isolated population cohorts. We removed seven individuals from GOMAP as outliers based on the first and second MDS components (Supplementary Figure 1).

A total of 2,582 samples passed QC (Supplementary Table 1; samples size of each diagnostic category: SCZ, n = 924; T2D, n = 822; T2D/SCZ, n = 505; other diagnosis, n = 331).

After removal of individuals failing QC, variants were filtered for call rates lower than 98%, a Hardy-Weinberg Equilibrium deviation p value < 1 × 10−8 and cluster separation scores below 0.4. In addition, we removed X-chromosomal markers not within the pseudo-autosomal region with heterozygous haploid genotypes in males.
total of 524,271 autosomal and X-chromosomal markers passed QC (Supplementary Table 2).

Since GOMAP is a cases-only sample collection, we selected two independent Greek cohorts, TEENAGE \textsuperscript{29} \((n = 413)\) and ARGO \((n = 712)\), as control data sets. ARGO comprises osteoarthritis cases and healthy controls from Larisa, Greece. Samples from all three cohorts formed a cluster in MDS analysis (Supplementary Figure 2).

**Imputation**

Following QC we merged GOMAP with 413 samples from TEENAGE \textsuperscript{27} and 712 from ARGO, an in-house Greek sample collection. We performed pre-phasing of the merged dataset in SHAPEIT \textsuperscript{30} and imputed the phased haplotypes with IMPUTE2 \textsuperscript{31} using a combined reference panel consisting of UK10K \textsuperscript{32}, 1000 Genomes \textsuperscript{33} and HELIC-MANOLIS \textsuperscript{28}. We filtered imputed genotypes for Hardy-Weinberg equilibrium deviation \((p < 1 \times 10^{-4})\), IMPUTE2 info scores < 0.4, and a minor allele frequency \((\text{MAF}) > 1\%\). A total of 14,528,340 markers passed imputation QC.

**GWAS**

We carried out a GWAS for each case-case and case-control combination in GOMAP using the ‘method --expected’ option, which performs an additive association test, adjusting for the first ten MDS components using SNPTEST version 2.5 \textsuperscript{34}.

**Genetic risk scores**

We constructed polygenic risk scores for T2D and SCZ in GOMAP based on effect size estimates from the DIAGRAM and PGC consortium, respectively. The risk score analyses are divided into two stages: first, we constructed using only established risk variants for each disease; next, we relaxed our inclusion criteria incrementally by using all variants falling below a given \(p\) value threshold.

**Established risk variants**

For SCZ, we obtained odds ratios (ORs) of 125 autosomal risk variants from the psychiatric genomics consortium (PGC) \textsuperscript{19} (Supplementary Table 3). We excluded three X-chromosomal markers of the original 128 independent variants identified by Ripke et al \textsuperscript{19}, as calculating scores for non-autosomal alleles is not straightforward.

We used 73 variants identified in a trans-ethnic meta-analysis \textsuperscript{15} for the T2D risk score. In order to match the ancestry of the base data as closely to GOMAP as possible, we looked up summary statistics of all independent variants (76 in total) identified in the trans-ethnic study \textsuperscript{15} in the DIAGRAMv3 stage 1 meta-analysis \textsuperscript{17} (Supplementary Tables 4) based on samples of European descent. Three of the 76 variants were not present in the DIAGRAMv3 data and therefore excluded.

We used PRSice version 1.25 \textsuperscript{35} to calculate the risk scores in GOMAP and test for an association between scores and phenotype. Briefly, for each variant the number of risk alleles in the target data (GOMAP) is multiplied by the log(OR) from the base data (DIAGRAM or PGC). The total score for an individual is the average score across all SNPs in the set. Following the approach described by Purcell et al \textsuperscript{36}, two logistic regression models are used to obtain the variance in phenotype explained (Nagelkerke’s pseudo \(R^2\)):

**Full model:**

\[
\text{Phenotype} \sim \text{Score} + C1 + C2 + C3 + C4 + C5 + C6 + C7 + C8 + C9 + C10
\]

**Null model:**

\[
\text{Phenotype} \sim C1 + C2 + C3 + C4 + C5 + C6 + C7 + C8 + C9 + C10
\]

In the full model, phenotypes are regressed on risk scores adjusting for the first ten multi-dimensional scaling (MDS) components; in the null model, phenotypes are regressed on MDS components only. Most, but not all studies contributing to the DIAGRAMv3 meta-analysis adjusted for sex; conversely, sex was not adjusted for in the individual GWAS included in the PGC-SCZ meta-analysis. We therefore decided not to add sex as a covariate in our risk score model. The final pseudo \(R^2\) estimate is obtained by:

\[
R^2_{\text{final}} = R^2_{\text{full}} - R^2_{\text{null}}
\]

A \(p\) value for association of score with phenotype was obtained from the full model. Risk score analysis was carried out in each pairwise comparison between the three disease groups and controls in GOMAP.

To assess whether the sample size difference between the single-disease and comorbid group in GOMAP affects the strength of the risk scores, we randomly downsampled the SCZ-only and T2D-only group to 500 individuals each and performed risk score analyses with this reduced set. We repeated this process 5,000 times and computed average pseudo \(R^2\) and \(p\) values.

**Genome-wide risk scores**

In addition to calculating risk scores based on established genome-wide significant risk variants, we performed polygenic scoring as implemented in PRSice \textsuperscript{35}, a pipeline automating data preparation in PLINK \textsuperscript{26} and risk score regression in R. First, \(P\) value informed linkage disequilibrium (LD) clumping was performed on the intersection of variants between the base summary statistics (DIAGRAM \textsuperscript{17} and PGC \textsuperscript{19}) and target data (GOMAP), using an \(r^2\) threshold of 0.1 and a window size of 250 kb. Next, alleles are matched between the base and
target data and ambiguous variants are removed to produce a final list of clumped variants used for the risk scores. Score calculations and regression analyses are conducted following the same procedure as outlined for the established risk variants. We performed risk score analyses at ten cumulative $p$ value thresholds: $p < 5 \times 10^{-8}$, $p < 0.001$, $p < 0.005$, $p < 0.05$, $p < 0.1$, $p < 0.2$, $p < 0.3$, $p < 0.4$, $p < 0.5$, $p < 1$; all variants below a given threshold in the base data were included in the score.

Summary statistics-based overlap analyses

We obtained genome-wide summary data for T2D from the DIAGRAMv3 meta-analysis\textsuperscript{17}, and for SCZ from the Psychiatric Genomics Consortium (PGC) meta-analysis\textsuperscript{19}. To assess the genetic overlap between the two data sets, we performed three complementary analyses, which have been described previously\textsuperscript{37} and are briefly outlined below.

**LD score regression**

LD score regression relies on the assumption that variants in strong LD with a causal variant will have a higher association statistic than variants in low LD. When comparing the effect estimates of two GWAS, LD score regression can be used to compute the overall (i.e. genome-wide) correlation between them.

We performed LD-score regression\textsuperscript{38} on the DIAGRAMv3\textsuperscript{17} and PGC\textsuperscript{19} summary statistics, using LD scores computed on the 1000 Genomes European sample\textsuperscript{39}.

**Regional colocalisation test**

We performed a Bayesian colocalisation analysis\textsuperscript{40} to test for the presence of association signals in distinct blocks across the genome. At each region the model uses $Z$-scores and standard errors from two association studies to generate posterior probabilities for each of five hypotheses:

**Hypothesis 0:** No causal variants

**Hypothesis 1:** One causal variant for disease 1.

**Hypothesis 2:** One causal variant for disease 2.

**Hypothesis 3:** One causal variant for disease 1 and 2.

**Hypothesis 4:** One causal variant each for disease 1 and 2.

Splitting the genome into uniform segments without accounting for LD structure can result in the double-counting of signals if segment boundaries happen to fall within an associated region. We downloaded LD-blocks pre-computed using the LDetect algorithm\textsuperscript{41} and the European sample of the 1000 Genomes Phase 1 data\textsuperscript{33} (https://bitbucket.org/nygcresearch/ldetect-data). The output of the test includes posterior probability estimates, as well as the highest absolute $Z$-score for each phenotype in a given region. We followed up regions with a high ($\geq 0.9$) posterior probability for either hypothesis 3 or 4 by taking the variants corresponding to the highest absolute $Z$-scores in DIAGRAMv3 and PGC-SCZ and querying their function and closest protein coding genes using the Ensembl REST API\textsuperscript{42}.

**Extent of shared signals**

To assess the extent of association signals common between DIAGRAMv3 and PGC-SCZ, we took all variants present in both data sets and performed $p$ value informed LD pruning ($r^2 > 0.1$) to obtain an independent set. We constructed $2 \times 2$ contingency tables of overlapping variants at ten cumulative $p$ value thresholds ($P_i$) by counting how many variants fell above and below each $P_i$ in DIAGRAMv3 and PGC-SCZ. We then tested for an excess of shared signals at each $P_i$ by applying a $\chi^2$ test, which gives an overlap $p$ value. Empirical overlap $p$ values were obtained by randomly permuting the GWAS $p$ values in each data set 1,000,000 times and repeating the test on each permuted set.

**Gene and pathway analysis**

We used MAGMA\textsuperscript{43} to perform gene and pathway analyses on the DIAGRAMv3 and PGC summary statistics separately. We annotated variants in each dataset to genes according to dbSNP version 135 coordinates and NCBI 37.3 gene definitions. We allowed for a 20 kilobase (kb) window around the transcription start and stop sites to also include proximal regulatory elements. We combined the results of the gene-level analysis into biological pathways using gene-set definitions from two comprehensive databases: the Molecular Signatures Database canonical pathways collection\textsuperscript{44}, comprising 1,329 manually curated gene-sets, and the Gene Ontology pathway database\textsuperscript{45}, comprising 6,166 automatically annotated gene-sets. Significance was defined as a false discovery rate (FDR) corrected $p$ value ($q$ value) < 0.05.

**Results**

**GWAS**

We performed six case-case and case-control genome-wide association studies in GOMAP and population controls (Supplementary Figures 6-9). There was no indication of inflation of test statistics, with lambda values ranging from 0.99 to 1.04 (Supplementary Figures 8-9).

We identified two genome-wide significant signals in the SCZplusT2D vs controls analysis (Table 2; Supplementary Figure 6c). The most strongly associated variant
Table 2 Top variant of genome-wide significant signals in the GOMAP GWAS analyses

| Variant         | GWAS                  | EA  | NEA | EAF | OR (95% CI)  | Info | P value  |
|-----------------|-----------------------|-----|-----|-----|--------------|------|----------|
| chr6:163319442  | SCZplusT2D vs Controls| T   | G   | 0.91| 3.81 (3.32-4.29) | 0.56 | 5.46E-09 |
| rs1449245       | SCZplusT2D vs Controls| T   | G   | 0.79| 1.96 (1.71-2.2) | 0.85 | 2.58E-08 |
| rs7903146       | T2D vs Controls       | T   | C   | 0.38| 1.66 (1.5-1.81) | 1.00 | 3.31E-11 |
| rs7903146       | T2D vs SCZ            | C   | T   | 0.61| 1.53 (1.39-1.67) | 1.00 | 1.09E-09 |
| rs17616243      | SCZ vs Controls       | T   | C   | 0.16| 2.03 (1.79-2.27) | 0.72 | 3.26E-09 |
| rs6598475       | T2D vs Controls       | T   | G   | 0.36| 1.56 (1.4-1.72) | 0.93 | 1.95E-08 |

*EA effect allele, NEA non-effect allele, EAF effect allele frequency, OR odd ratio, CI confidence interval*

Table 3 Overlap analysis between DIAGRAM and PGC summary statistics

| \(P_f\) value | Variants | \(\chi^2\) | \(P\) value | \(P_{perm}\) value |
|--------------|----------|------------|-------------|---------------------|
| 0.5          | 58504    | 1.4        | 2.30E-01    | 2.32E-01            |
| 0.1          | 6247     | 39.7       | 3.00E-10    | 0.00E+00            |
| 0.05         | 2324     | 40.9       | 1.60E-10    | 0.00E+00            |
| 0.04         | 1749     | 53.5       | 2.50E-13    | 0.00E+00            |
| 0.03         | 1180     | 49         | 2.50E-12    | 0.00E+00            |
| 0.02         | 658      | 32.4       | 1.30E-08    | 0.00E+00            |
| 0.01         | 287      | 41.4       | 1.30E-10    | 0.00E+00            |
| 0.005        | 125      | 37.7       | 8.10E-10    | 0.00E+00            |
| 0.001        | 19       | 14.2       | 1.70E-04    | 8.30E-04            |
| 5.00E-04     | 10       | 13.8       | 2.00E-04    | 2.00E-03            |

For each \(P_f\) value threshold \(P_f\) the number of independent variants overlapping at this threshold is given, along with the resulting chi-squared statistic \(\chi^2\), \(p\) value \(P\) and empirical \(p\) value obtained by permutations \(P_{perm}\). residues within an intron of the PACRG gene (chr6:163319442, G/A, effect allele (EA) G, effect allele frequency (EAF) 0.91, OR 3.81 [95% CI: 3.32–4.29], \(p\) value = 5.46 x 10\(^{-9}\)). The second signal is located in an intron of RP11-587H10.2 on chromosome 8 (rs1449245, EA A, EAF 0.79, OR 1.96 [95% CI 1.77–2.20], \(p\) value = 2.58 x 10\(^{-8}\)).

Three further signals reached genome-wide significance in other analyses (Table 2): an intronic single nucleotide polymorphism (SNP) in TCF7L2 (rs7903146, EA T, EAF 0.38), a well-established T2D risk gene\(^\text{17}\), in the T2D vs controls (OR 1.66 [95% CI 1.50-1.80], \(p\) value = 3.31 x 10\(^{-11}\)) and T2D vs SCZ analyses (OR 1.53 [95% CI: 1.39–1.67], \(p\) value = 1.09 x 10\(^{-9}\)); an intrinsic SNP in BMPR1B (rs17616243, EA T EAF 0.16, OR: 2.03 [95% CI: 1.79–2.27], \(p\) value = 3.26 x 10\(^{-9}\)) in the SCZ vs controls GWAS; and an intrinsic SNP in PCSK6 in the T2D vs controls GWAS (rs6598475, EA T, EAF 0.36, OR: 1.56 [95% CI: 1.40–1.72], \(p\) value = 1.95 x 10\(^{-8}\)). (Table 3)

Table 4 Overlap analysis between DIAGRAM and PGC summary statistics

| Variant         | GWAS                  | EA  | NEA | EAF | OR (95% CI)  | Info | P value  |
|-----------------|-----------------------|-----|-----|-----|--------------|------|----------|
| chr6:163319442  | SCZplusT2D vs Controls| T   | G   | 0.91| 3.81 (3.32-4.29) | 0.56 | 5.46E-09 |
| rs1449245       | SCZplusT2D vs Controls| A   | G   | 0.79| 1.96 (1.71-2.2) | 0.85 | 2.58E-08 |
| rs7903146       | T2D vs Controls       | T   | C   | 0.38| 1.66 (1.5-1.81) | 1.00 | 3.31E-11 |
| rs7903146       | T2D vs SCZ            | C   | T   | 0.61| 1.53 (1.39-1.67) | 1.00 | 1.09E-09 |
| rs17616243      | SCZ vs Controls       | T   | C   | 0.16| 2.03 (1.79-2.27) | 0.72 | 3.26E-09 |
| rs6598475       | T2D vs Controls       | T   | G   | 0.36| 1.56 (1.4-1.72) | 0.93 | 1.95E-08 |

*EA effect allele, NEA non-effect allele, EAF effect allele frequency, OR odd ratio, CI confidence interval*

Genetic risk scores

We performed genetic risk score analyses of SCZ and T2D for each pairwise case-case and case-control combination in GOMAP (Fig. 1). In the case-control analyses, risk scores for SCZ and T2D were significantly associated with these respective disorders (SCZ \(R^2 = 1.7\%\), \(p\) value = 5.25 x 10\(^{-9}\); T2D \(R^2 = 6.8\%\), \(p\) value = 6.12 x 10\(^{-27}\)), serving as a positive control for the validity of the included variants and patient groups. Conversely, risk scores for one disorder were not associated with the other in the case-control comparisons. In the comorbid sample both SCZ and T2D risk scores were significantly associated with phenotype (SCZ risk score \(p\) value = 7.17 x 10\(^{-5}\); T2D risk score \(p\) value = 4.14 x 10\(^{-4}\)), with \(R^2\) values lower than those in the single-disease groups (SCZ risk score \(R^2 = 1\%\); T2D \(R^2 = 0.8\%\)).

In the comparison between T2D and SCZ cases, risk scores for T2D explained 9.3% of variance (\(p\) value = 8.04 x 10\(^{-28}\)) and risk scores for SCZ explained 3.4% of variance (\(p\) value = 8.06 x 10\(^{-12}\)). These \(R^2\) values may be higher than in the case-control analyses due to the fact that controls are population based and not ascertained for either SCZ or T2D status; it is therefore plausible that a subset of controls carries risk alleles for these disorders. In the comparison of individuals with SCZ to those with SCZ and T2D, SCZ risk scores and their \(R^2\) values were not significantly associated with disease. This is expected, as both sample groups are likely to be enriched for SCZ risk alleles. Interestingly, the \(R^2\) estimate of the T2D variant risk scores in the T2D vs. SCZplusT2D analysis was intermediate in magnitude to that measured in the SCZ vs. SCZplusT2D and the SCZ vs T2D analyses. This can be recapitulated by examining the average T2D scores across the different sample groups (Fig. 2): the average score of the SCZplusT2D sample is higher than for the SCZ-only sample but lower than for the T2D-only sample, indicating that the comorbid group is enriched for T2D risk alleles compared to the SCZ-only group.

To determine whether the observed strength of association of the risk scores was influenced by the difference
in sample size among the single-disease and comorbid groups, we repeated the risk score analyses with equally-sized (n = 500), randomly down-sampled T2D- and SCZ-only cases. Risk scores significantly associated with phenotype using the full data set remained significant even with the decreased sample size (p < 0.05) (Supplementary Figure 3).

It has been shown that the inclusion of variants not reaching genome-wide significance can enhance the power of genetic risk scores. We constructed polygenic scores at ten cumulative p value thresholds using the same base data sets (DIAGRAMv3 and PGC-SCZ) as for the established variant scores. For the SCZ scores, the most stringent threshold (p < 5 × 10^{-8}) resulted in lower levels...
of association and pseudo-$R^2$ estimates than the established variant score, due to the fact that some of the variants included in the latter had $p > 5 \times 10^{-8}$ in the PGC-SCZ discovery data, which was used here, and were therefore excluded. At more permissive $p$ value thresholds the strength of association increased by several orders of magnitude compared to the established variant scores for all but the SCZ vs SCZplusT2D and T2D vs Controls analyses (Supplementary Figure 4). While pseudo-$R^2$ also increased at the first increments variant inclusion, they plateaued or even decreased slightly for thresholds with $p > 0.005$. While more relaxed thresholds will include more variants with true effects, they will inevitably also add more null variants contributing to noise.

Unlike the SCZ score, T2D scores demonstrated decreasing levels of association as more variants were included in the risk score (Supplementary Figure 5). This can be explained by the fact that only 21 of the 73 variants used for the established loci score were retained after LD clumping, again due to their strength of association in the DIAGRAMv3 discovery data. In total, only 15 variants were included at the most stringent $p$ value threshold, whereas over 1,000 were used at $p = 2.2 \times 10^{-9}$. The strongest SCZ signal occurred at rs3117574 (OR 0.85, 95% CI $0.82-0.89$, $p = 6.71 \times 10^{-10}$), a variant in the $5'$ untranslated region of $MSH5$, a protein involved in meiotic recombination and DNA mismatch repair.

The second region falls within the major histocompatibility complex on chromosome 6, which is known to harbour several SCZ and T2D loci.$^{17,19}$ There were three variants with the same effect size for T2D, one of which lies in an intron of $SLC44A$ (rs9267658, OR 0.89, 95% CI $0.85-0.94$, $p = 2.2 \times 10^{-9}$). The strongest SCZ signal occurred at rs10189857 (OR 0.89, 95% CI $0.82-0.89$, $p = 6.71 \times 10^{-10}$), a variant in the $5'$ untranslated region of $MSH5$, a protein involved in meiotic recombination and DNA mismatch repair.

The third region resides on chromosome 7, harbouring both a known T2D locus downstream of $KLF14$ (top variant in DIAGRAMv3: rs10954284, $p = 1.20 \times 10^{-8}$) and a known SCZ variant at rs7801375 (PGC $p = 2.26 \times 10^{-9}$)$^{19}$. The fourth region, identified on chromosome 8, does not contain any known T2D or SCZ associated variants. The strongest signals in that region occur at rs11993663 for SCZ (PGC $p = 1.46 \times 10^{-7}$) and rs17150816 for T2D (DIAGRAMv3 $p = 1.60 \times 10^{-7}$).

Finally, a region identified on chromosome 15 encompasses a known SCZ locus in the VPS13C gene (top variant in PGC: rs12903146, $p = 3.00 \times 10^{-10}$), as well as the C2CD4A-C2CD4B locus, which has been associated with T2D in East Asian populations and also replicated in Europeans (top variant in DIAGRAMv3: rs8026735, $p = 2.50 \times 10^{-7}$)$^{37}$. 

**Summary statistics-based overlap analyses**

We investigated the genetic overlap between summary data from the DIAGRAMv3 meta-analysis for T2D$^{17}$ and the PGC meta-analysis for SCZ$^{19}$ using both genome-wide and regional approaches.

**LD score regression**

There was no significant correlation between these data sets on a genome-wide scale ($r^2 = -0.01$, SE = 0.04, $p$ value = 0.82; Supplementary Methods), as previously reported elsewhere$^{38}$. 

**Colocalisation analysis**

We employed a Bayesian colocalisation analysis to search for genomic regions that potentially exert pleiotropic effects. For each region, the method returns posterior probabilities for the five tested hypotheses, as well as the maximum absolute $Z$-scores found in each of the two input data sets; in some cases, there is more than one variant with the same $Z$-score (i.e. effect estimate) in a region.

There were no regions with a high posterior probability (>0.9) of containing one causal variant common to both diseases. However, five regions had a high posterior probability of harbouring two distinct causal variants (Supplementary Table 3).

The first of these regions is located on chromosome 2 and includes nominally significant SCZ variant (top variant in PGC: rs10189857, $p = 5.14 \times 10^{-7}$)$^{19}$ in an intron of $BCL11A$, and a T2D risk locus upstream of the same gene (top variant in DIAGRAMv3: rs243021, $p = 3 \times 10^{-15}$)$^{46}$.

The second region falls within the major histocompatibility complex on chromosome 6, which is known to harbour several SCZ and T2D loci.$^{17,19}$ There were three variants with the same effect size for T2D, one of which lies in an intron of $SLC44A$ (rs9267658, OR 0.89, 95% CI $0.85-0.94$, $p = 2.2 \times 10^{-9}$). The strongest SCZ signal occurred at rs3117574 (OR 0.85, 95% CI $0.82-0.89$, $p = 6.71 \times 10^{-10}$), a variant in the $5'$ untranslated region of $MSH5$, a protein involved in meiotic recombination and DNA mismatch repair.

The third region resides on chromosome 7, harbouring both a known T2D locus downstream of $KLF14$ (top variant in DIAGRAMv3: rs10954284, $p = 1.20 \times 10^{-8}$) and a known SCZ variant at rs7801375 (PGC $p = 2.26 \times 10^{-9}$)$^{19}$. The fourth region, identified on chromosome 8, does not contain any known T2D or SCZ associated variants. The strongest signals in that region occur at rs11993663 for SCZ (PGC $p = 1.46 \times 10^{-7}$) and rs17150816 for T2D (DIAGRAMv3 $p = 1.60 \times 10^{-7}$).

Finally, a region identified on chromosome 15 encompasses a known SCZ locus in the VPS13C gene (top variant in PGC: rs12903146, $p = 3.00 \times 10^{-10}$), as well as the C2CD4A-C2CD4B locus, which has been associated with T2D in East Asian populations and also replicated in Europeans (top variant in DIAGRAMv3: rs8026735, $p = 2.50 \times 10^{-7}$)$^{37}$. 

**Extent of shared signals**

We assessed the extent of shared association signals between DIAGRAMv3 and PGC-SCZ at ten different $p$-value thresholds ($P_i$) and found significant evidence for overlap ($p_{perm} < 0.05$) at all but one $P_i$ (Table 2). Of the 19 variants overlapping at $P_i = 0.001$, five are located in known T2D loci, and four within known SCZ loci. One of the variants identified at this $P_i$, rs6488868, is a synonymous SNP in $SBNO1$, and in partial LD with both a known T2D (rs1727313, $r^2 = 0.53$) and a known SCZ (rs2851447, $r^2 = 0.45$) risk variant. The two risk variants lie in the $3^{'}$UTR and in an intron of $MPHOSPH9$, respectively, and are also in LD with each other ($r^2 = 0.79$). Other variants fall within or around several genes previously linked to SCZ or T2D, such as $CACNA1$, $HLA- B$, $PROX1$ and $BCL11A$.$^{17,19}$ (Supplementary Table 4).

**Gene and pathway analysis**

We tested for enrichment of association signals in genes and pathways in the DIAGRAM and PGC summary statistics. We did not identify any pathways that were significantly associated ($q$ value < 0.05) with both SCZ and
T2D. In the gene-level analysis, 29 genes had a $q$ value $< 0.05$ in both data sets (Supplementary Table 5). Ten of the genes have been previously associated with SCZ and/or T2D. Of note, variants in or in close proximity to ZFAND6, PROX1, and HLA-B were also found to overlap at $P_1 = 0.001$. SLC44A4, which is strongly associated with SCZ ($q$ value $= 4.73 \times 10^{-11}$), falls within the region on chromosome 6 identified in the colocalisation analysis.

**Discussion**

We investigated the genetic overlap between SCZ and T2D, using summary statistics from large-scale meta-analyses and genome-wide genotype data from a dedicated collection of individuals with SCZ, T2D or both disorders. The work presented here benefits from clinically ascertainment diagnoses and robust base data sets used to construct the risk scores. Due to the limited sample size and, consequently, low power to detect genetic associations in GOMAP, we did not expect to identify novel genome-wide significant loci, but rather to harness the comorbid patient group for risk score analyses. The two genome-wide significant signals identified in the SCZplusT2D vs controls GWAS map to introns of PACRG and RP11-587H10.2. PACRG has been associated with the risk of leprosy$^{48}$, while RP11-587H10.2, a long non-coding RNA, is of unknown function. Replication of these signals in independent data sets is required to establish or refute them as novel associations.

Our main finding arises from the risk score analyses, which demonstrated that the SCZplusT2D sample is enriched for both SCZ and T2D risk alleles compared to controls, in line with the increased prevalence of T2D among schizophrenia patients being at least partly due to genetic predisposition.$^{2,3}$ Patients suffering from both diseases had SCZ risk scores comparable to the SCZ-only group but fell between the SCZ-only and T2D-only groups for T2D risk scores. This implies that patients with comorbid SCZ and T2D carry almost the same SCZ risk allele profile as SCZ patients without T2D but have fewer of risk-increasing variants for T2D than T2D patients without comorbid SCZ. Two conclusions might be drawn from this: first, at least part of the risk for T2D in SCZ patients is driven by genetic predisposition to T2D, rather than antipsychotic use alone; and second, the comorbid group appear to have a less strong T2D genetic risk profile compared to T2D-only patients. This is in line with environmental factors, including response to anti-psychotic treatment and sedentary lifestyle, contributing to T2D risk. Such factors might exacerbate an otherwise moderate genetic predisposition to T2D.

To our knowledge, three other studies have to date compared risk scores for T2D and SCZ.$^{36,49,50}$ Purcell et al. first performed SCZ risk scores analysis in a T2D sample but did not identify a significant correlation between scores and phenotype$^{36}$, potentially due to the relatively low sample sizes available at the time ($\sim 3300$ cases for SCZ; $\sim 1900$ cases for T2D). More recently, a study investigating the genetic liability to SCZ in immune-related disorders found a weak association between SCZ risk scores and T2D.$^{40}$ The investigators used an earlier release of the PGC-SCZ summary data$^{20}$ with lower sample numbers than currently available. One study has previously reported an association between T2D risk scores based on DIAGRAM summary statistics and self-reported diabetes (any type) in individuals with psychosis, but did not detect an association when repeating the analysis for SCZ risk scores$^{52}$.

The SNP-based overlap analysis highlighted one region where a known T2D and a known SCZ signal map to the same locus in the MPHOSPH9 gene$^{15,19}$, which encodes a phosphoprotein highly expressed in the cerebellum. This gene has been previously associated with multiple sclerosis,$^{51}$ however, its function is not well understood. We also identify PROX1 as a potentially pleiotropic locus based on the gene analysis and the SNP-based overlap test. PROX1 has been previously implicated in each of T2D and SCZ, and acts both as a transcriptional activator and repressor depending on the cellular context. It has been implicated in murine beta-cell development$^{52}$, as well as in neurogenesis in humans$^{53}$. One possible explanation for the cross-phenotype associations of these loci might be that they influence T2D and SCZ by acting in different biological pathways. However, follow-up in functional (e.g. expression or proteomic) data is needed in order to evaluate this hypothesis.

In this study, we have shown that genetic predisposition to SCZ and genetic predisposition to T2D are both associated with comorbidity. Future studies with larger sample sizes and detailed phenotype information (ideally including longitudinal medication data) will be necessary to precisely disentangle the shared genetic basis of SCZ and T2D.

**Data availability**

Genetic data for the GOMAP study has been deposited at the European Genome-Phenome Archive (EGA) which is hosted at the EBI and the CRG, under accession number EGAS00001002723.

**Acknowledgements**

We thank all participants of the GOMAP study for their contribution to this project. This work was funded by the Wellcome Trust (WT098051).

**Author details**

1Human Genetics, Wellcome Trust Sanger Institute, Hinxton CB10 1HH, UK.
2Strangeways Research Laboratory, University of Cambridge, 2 Worts’ Causeway, Cambridge CB1 8RN, UK.
3Medical School, National and Kapodistrian University of Athens, Athens 11528, Greece.
45th Department, Dromokateio Psychiatric Hospital, Athens 124 61, Greece.
5Department of Oncology and Metabolism, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK.
6William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 1M 6BQ, UK.
7University of Split, Ljivanska ul. 5, Split 21000, Croatia.
8Department of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
Gastroenterology, Gennimatas General Hospital, Athens 11527, Greece.
3Department of Biology, National and Kapodistrian University of Athens,
Athens, Panepistimioupolis, Ano Ilisia, Athens 15771, Greece. 4Early Psychosis
Unit, 1st Department of Psychiatry, Eginition Hospital, Medical School,
National and Kapodistrian University of Athens, Athens 11527, Greece. 5Department of
Nutrition-Dietetics, Harokopio University, 17671 Athens, Greece. 61st
Department of Psychiatry, Eginition Hospital, Medical School, National and
Kapodistrian University of Athens, Athens 11528, Greece. 7Diabetes Centre,
2nd Department of Internal Medicine, Hippokration General Hospital, Medical
School, National and Kapodistrian University of Athens, Athens 11527, Greece.
81st Department of Propaedeutic and Internal Medicine, National and
Kapodistrian University of Athens, Athens 11527, Greece. 9Faculty of Medicine,
Department of Biology, University of Thessaly, 41500 Larissa, Greece. 10Institute of
Translational Genomics, Helmholtz Zentrum München, German Research Center
for Environmental Health, Neuherberg, Germany

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-018-0304-6).

Received: 17 May 2018 Accepted: 31 July 2018
Published online: 23 November 2018

References
1. Rouillon, F. & Sorbara, F. Schizophrenia and diabetes: epidemiological data. Eur.
Psychiatry 20, S345–S348 (2005).
2. Lin, P. I. & Shuldiner, A. R. Rethinking the genetic basis for comorbidity of
schizophrenia and type 2 diabetes. Schizophr. Res. 123, 234–243 (2010).
3. Suvissa, J., Keinänen, J., Eskelinen, S. & Mantere, O. Diabetes and schizo-
phrenia. Curr. Diab. Rep. 16, 16 (2016).
4. Holt, R. C. G. & Mitchell, A. J. Diabetes mellitus and severe mental illness:
mechanisms and clinical implications. Nat. Rev. Endocrinol. 11, 79–89 (2015).
5. Young, S. L., Taylor, M. & Lawrie, S. M. “First do no harm.” A systematic review
of the prevalence and management of antipsychotic adverse effects. J.
Psychopharmacol. 29, 353–362 (2015).
6. Vancampfort, D. et al. Diabetes mellitus in people with schizophrenia, bipolar
disorder and major depressive disorder: a systematic review and large scale
meta-analysis. World Psychiatry 15, 166–174 (2016).
7. Correll, C. U., Detraux, J., De Lepeleire, J. & De Hert, M. Effects of antipsychotics,
antidepressants and mood stabilizers on risk for physical diseases in people
with schizophrenia, depression and bipolar disorder. World Psychiatry 14,
119–136 (2015).
8. Smith, M. et al. First- vs. second-generation antipsychotics and risk for diabetes
in schizophrenia. Systematic review and meta-analysis. Br. J. Psychiatry 192,
402–411 (2008).
9. Zhang, J. P. et al. Genetic variation in BDNF is associated with antipsychotic
treatment resistance in patients with schizophrenia. Schizophr. Res. 146,
285–288 (2013).
10. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with
chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).
11. Prabakaran, S. et al. Mitochondrial dysfunction in schizophrenia: evidence for
compromised brain metabolism and oxidative stress. Mol. Psychiatry 9,
684–697 (2004).
12. van Beveren, N. J. M. et al. Evidence for disturbed insulin and growth hormone
signalling as potential risk factors in the development of schizophrenia. Transl.
Psychiatry 4, e430 (2014).
13. Rajkumar, A. P. et al. Endogenous and antipsychotic-related risks for diabetes
mellitus in young people with schizophrenia: a danish population-based
cohort study. Am. J. Psychiatry 174, 686–694 (2017).
14. Pillinger, T. et al. Impaired glucose homeostasis in first-episode schizophrenia:
a systematic review and meta-analysis. JAMA Psychiatry 74, 261 (2017).
15. Mahajan, A. et al. Genome-wide trans-ancestry meta-analysis provides insight
into the genetic architecture of type 2 diabetes susceptibility. Nat. Genet. 46,
234–244 (2014).
16. Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536,
41–47 (2016).
17. Morris, A. D. P. et al. Large-scale association analysis provides insights into the
genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44,
981–990 (2012).
18. Scott, R. A. et al. An expanded genome-wide association study of type 2 diabetes
in Europeans. Diabetes 66, 2888–2902 (2017).
19. Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic
loci. Nature 511, 421–427 (2014).
20. Ripke, S. et al. Genome-wide association study identifies five new schizo-
phrenia loci. Nat. Genet. 43, 969–976 (2011).
21. Ripke, S. et al. Genome-wide association analysis identifies 13 new risk loci for
schizophrenia. Nat. Genet. 45, 1150–1159 (2013).
22. Locke, A. E. et al. Genetic studies of body mass index yield new insights for
obesity biology. Nature 518, 197–206 (2015).
23. American Psychiatric Association. Diagnostic And Statistical Manual Of Mental
Disorders 5th edn, American Psychiatric Publishing: Arlington, VA (2013).
24. Association, A. D. Standards of medical care in diabetes—2014. Diabetes Care
37, S14–S50 (2014).
25. Panoutsopoulou, K. et al. Genetic characterization of Greek population isolates
reveals strong genetic drift at missense and trait-associated variants. Nat.
Commun. 5, 5345 (2014).
26. Chang, C. C. et al. Second-generation PLINK rising to the challenge of larger
and richer datasets. Gigascience 4, 1–16 (2015).
27. Ntalla, I. et al. Replication of established common genetic variants for adult
bmi and childhood obesity in Greek adolescents: the TEENAGE study. Ann.
Hum. Genet. 77, 268–274 (2013).
28. Southam, L. et al. Whole genome sequencing and imputation in isolated
populations identify genetic associations with medically-relevant complex
traits. Nat. Commun. 8, 15606 (2017).
29. Ntalla, I. et al. Body composition and eating behaviours in relation to dieting
involvement in a sample of urban Greek adolescents from the TEENAGE
(TEENs of Attica: genes & environment) study. Public Health Nutr. 17, 561–568
(2013).
30. Delaneau, O. & Marchini, J. Integrating sequence and array data to create an
improved 1000 Genomes Project haplotype reference panel. Nat. Commun. 5,
3934 (2014).
31. Howie, B. N., Donnelly, P., Marchini, J., Hardy, J. & Abecasis, G. A flexible and
accurate genotype imputation method for the next generation of genome-
wide association studies. PLoS Genet. 5, e1000529 (2009).
32. Walter, K. et al. The UK10K project identifies rare variants in health and disease.
Nature 526, 82–90 (2015).
33. Auton, A. et al. A global reference for human genetic variation. Nature 526,
61–68 (2015).
34. Marchini, J., Haines, J., Myers, S., McVean, G. & Donnelly, P. A new multipoint
method for genome-wide association studies by imputation of genotypes.
Nat. Genet. 39, 906–913 (2007).
35. Euesden, J., Lewis, C. M., O’Reilly, P. F. & Reilly, P. F. O. PRSice: polygenic risk
score software. Bioinformatics 31, 1466–1468 (2014).
36. Purcell, S. M. et al. Common polygenic variation contributes to risk of schi-
zophrenia and bipolar disorder. Nature 460, 748–752 (2009).
37. Hackinger, S. et al. Evaluation of shared genetic aetiology between osteoar-
thritis and bone mineral density identifies SMAD3 as a novel osteoarthritis risk
locus. Hum. Mol. Genet. 19, 324–331 (2017).
38. Bulk-Sullivan, B. et al. An atlas of genetic correlations across human diseases
and traits. Nat. Genet. 47, 1236–1241 (2015).
39. Bulk-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295
(2015).
40. Pickrell, J., Berisa, T., Segurel, L., Tung, J. Y., Hinds, D. Detection and inter-
pretation of shared genetic influences on 42 human traits. Nat. Genet. 48,
709–717 (2015).
41. Berisa, T. & Pickrell, J. K. Approximately independent linkage disequilibrium
blocks in human populations. Bioinformatics 32, 283–285 (2016).
42. Yates, A. et al. The ensemble REST API: ensemble data for any language. Bioin-
formatics 31, 143–145 (2015).
43. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219 (2015).
44. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. 102, 15545–15550 (2005).
45. Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).
46. Voight, B. F. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 579–589 (2010).
47. Yamauchi, T. et al. A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat. Genet. 42, 864–868 (2010).
48. Mira, M. T. et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427, 636–640 (2004).
49. Padmanabhan, J. L. et al. Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives. J. Psychiatr. Res. 77, 52–58 (2016).
50. Stringer, S., Kahn, R. S., de Witte, L. D., Ophoff, R. A. & Derks, E. M. Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr. Res. 159, 347–352 (2014).
51. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immun. 11, 397–405 (2010).
52. Paul, L. et al. Lack of Prox1 Downregulation Disrupts the Expansion and Maturation of Postnatal Murine β-Cells. Diabetes 65, 687–698 (2016).
53. Holzmann, J., Hennchen, M. & Rohrer, H. Prox1 identifies proliferating neuroblasts and nascent neurons during neurogenesis in sympathetic ganglia. Dev. Neurobiol. 75, 1352–1367 (2015).